Medical treatment of adult patients with X-linked hypophosphatemia

Seiji Fukumoto

doi:10.1093/jbmr/zjag137

September 15, 2026Journal of Bone and Mineral Research

Medical treatment of adult patients with X-linked hypophosphatemia

View at Publisher

Ask AI

Bookmark

Share

Key Points

Review and assess current medical therapies used to manage persistent phosphate wasting and bone complications in adult patients with X-linked hypophosphatemia.
Clinical review examining evidence-based pharmacological treatments and management protocols for adults with X-linked hypophosphatemia.
Contrasts conventional management using oral phosphate salts and active vitamin D analogs against targeted therapy using burosumab, a monoclonal antibody directed against fibroblast growth factor 23.
Identifies key treatment goals in adulthood, including promoting pseudofracture healing, alleviating persistent musculoskeletal pain, and minimizing long-term therapy-related toxicities.

Implication

Clinical review highlights medical strategies for adult X-linked hypophosphatemia, indicating improved avenues to relieve bone pain and correct mineral balance.

Abstract

Seiji Fukumoto; Medical treatment of adult patients with X-linked hypophosphatemia, Journal of Bone and Mineral Research, , zjag137, https://doi.org/10.109

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Seiji Fukumoto (2026) studied this question.

synapsesocial.com/papers/6aabb8135f706d05830e7a82 https://doi.org/10.1093/jbmr/zjag137

View at Publisher

Ask AI

Bookmark

Share

Medical treatment of adult patients with X-linked hypophosphatemia

Key Points

Implication

Abstract

Discussion

Cite This Study

Medical treatment of adult patients with X-linked hypophosphatemia

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Journal of Bone and Mineral Research

Keep reading

More related papers

More from Journal of Bone and Mineral Research